The End of the IV Drip? How a Wearable Gadget is Rewriting Cancer Care in Japan

CINCINNATI, OH – October 19, 2026 — For decades, the defining image of cancer treatment has been the intravenous drip—a slow, tethered reality that anchors patients to clinic chairs for hours. But the architecture of oncology care is undergoing a quiet, mechanical revolution. Today, Cincinnati-based Enable Injections, in partnership with pharmaceutical giant Sanofi, announced that Japan’s Ministry of Health, Labour and Welfare has approved the CirCLIQ Injector for the administration of Sarclisa (isatuximab).

This isn't just another regulatory nod; it represents a fundamental shift in the commercial and clinical strategy of biologic delivery. Powered by Enable’s enFuse On-Body Delivery System, the CirCLIQ Injector is the first on-body injector approved for anticancer treatment in Japan. It allows patients battling multiple myeloma to receive their subcutaneous formulation of Sarclisa with the push of a button, dramatically compressing treatment times and untethering them from the traditional clinical apparatus.

The approval covers the use of the device for adult patients across multiple indications, including in combination with pomalidomide and dexamethasone or carfilzomib for relapsed or refractory multiple myeloma, and in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed cases. By transforming a clinical event into a wearable experience, Sanofi and Enable Injections are tapping into a broader cultural demand for healthcare autonomy—a trend that will define the 2026 consumer experience.

The Device as the Differentiator in a Crowded Market

To understand the strategic gravity of this approval, one must look at the fiercely competitive landscape of multiple myeloma treatments. The market is dominated by anti-CD38 therapies, with Johnson & Johnson’s daratumumab holding a formidable monopoly. For Sanofi to carve out a larger share of this lucrative market, competing solely on molecular efficacy is no longer enough. The battleground has shifted to patient experience and delivery mechanics.

Sanofi’s deployment of the CirCLIQ injector is a masterclass in using device innovation as a commercial differentiator. Sarclisa is now the first anticancer treatment to be administered through an on-body injector, and the only anti-CD38 monoclonal antibody for multiple myeloma that offers the flexibility of both on-body injector and manual subcutaneous administration.

"This approval is another important milestone in our mission to expand access to novel drug delivery solutions around the world," said Michael D. Hooven, Chairman and CEO of Enable Injections. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan and to support an innovative treatment option for people living with multiple myeloma. As the adoption of subcutaneous delivery continues to grow globally, we're excited to help our pharmaceutical partners bring more therapies to patients."

By offering a device that adheres to the body and allows for light movement during administration, Sanofi is directly addressing the time toxicity of cancer care. Patients are increasingly viewing their treatment options through the lens of lifestyle preservation. A therapy that offers comparable efficacy but returns hours of lost time to the patient possesses a profound competitive advantage.

The IRAKLIA Data: Proving the Push-Button Approach

The transition from intravenous infusion to a purely mechanical, wearable injector requires an airtight clinical rationale. The regulatory approval was heavily anchored by the Phase 3 IRAKLIA trial, which evaluated the efficacy and safety of subcutaneous isatuximab in relapsed or refractory multiple myeloma patients.

The data reveals a compelling narrative of non-inferiority coupled with stark improvements in safety profiles. Subcutaneous isatuximab delivered via the on-body injector plus pomalidomide and dexamethasone yielded an Objective Response Rate of 71.1 percent, mirroring the 70.5 percent observed in the intravenous arm. Furthermore, rates of Very Good Partial Response or better stood at 46.4 percent for the subcutaneous group versus 45.9 percent for the intravenous group. The trial also successfully met its co-primary endpoint regarding trough concentrations at steady state.

But the most striking metric lies in the reduction of infusion-related reactions. While 25 percent of patients receiving intravenous Sarclisa experienced infusion reactions, that number plummeted to a mere 1.5 percent for those using the subcutaneous formulation. Local injection site reactions were practically negligible, occurring in only 0.4 percent of on-body injections, with nearly all classified as Grade 1.

Enable’s enFuse platform itself is a marvel of modern biomedical engineering. Originating from intellectual property developed at Cincinnati Children’s Hospital, the device utilizes a hidden, retractable needle that is shorter and thinner than traditional counterparts. It is designed to deliver high-volume medications—up to 50 milliliters—subcutaneously. Across rigorous clinical evaluations, the device demonstrated a staggering 99.9 percent delivery success rate for the full dose, proving that mechanical simplicity can yield clinical precision.

Unburdening Japan’s Healthcare Infrastructure

Beyond the individual patient experience, the systemic implications of this approval are particularly acute in Japan. The country is grappling with a rapidly aging demographic and a corresponding surge in oncology demands. Multiple myeloma currently ranks as the third most common hematologic malignancy in Japan, with incidence rates climbing steadily.

This demographic reality places immense strain on the nation's healthcare infrastructure. Hospital capacity bottlenecks and nursing labor shortages are critical pain points. Intravenous infusions require dedicated chair time, specialized equipment, and constant monitoring by oncology nurses. By shifting to a subcutaneous on-body injector that administers therapy in minutes rather than hours, clinics can dramatically increase their throughput.

Industry analysts note that intravenous-to-subcutaneous transitions have dramatically compressed administration time across oncology, offering a vital release valve for overtaxed healthcare systems. Alleviating the nursing workload allows highly trained medical staff to redirect their focus toward complex patient care rather than routine infusion monitoring.

Furthermore, the economic efficiencies introduced by the CirCLIQ Injector will likely play a crucial role in its commercial trajectory within Japan's National Health Insurance system. The Central Social Insurance Medical Council, which dictates drug and device pricing, increasingly relies on Health Economics and Outcomes Research. The tangible reduction in healthcare resource utilization—fewer hospital hours, reduced need for managing infusion reactions, and optimized staff allocation—presents a compelling economic argument for favorable reimbursement structures.

The Future of Conscious Consumption in Medicine

Enable Injections’ success in Japan—following recent approvals in the United States and Europe—signals a broader maturation of the wearable drug delivery market. Backed by over 314 million dollars in funding, Enable is leveraging a modular scalable manufacturing approach to meet global demand.

As we look toward the healthcare landscape of the late 2020s, the intersection of commercial strategy and patient-centric design is becoming the defining metric of success. Pharmaceutical companies are realizing that the molecule is only half the equation; the delivery mechanism is the interface through which the patient experiences the brand.

The approval of the CirCLIQ Injector in Japan is a testament to this reality. It acknowledges that patients are not merely passive recipients of medical care, but consumers whose time, comfort, and dignity hold immense value. By replacing the intravenous pole with a discreet, push-button wearable, the industry is taking a vital step toward a future where life-saving treatments adapt to the patient, rather than forcing the patient to adapt to the treatment.